SubsidieMeestersA minimally invasive and durable endograft fastening solution for Abdominal Aortic Aneurysm (AAA)
Aortoseal is an innovative implant for endovascular aneurysm repair that combines the stability of open surgery with the safety of EVAR, aiming to improve patient outcomes and save healthcare costs.
Projectdetails
Introduction
Abdominal aortic aneurysm (AAA) is a focal enlargement of the abdominal aorta below the renal arteries and is found in up to 4 million patients globally each year. If left untreated, it can be fatal, so it is imperative to provide early, prophylactic treatment before a rupture occurs.
Treatment Options
The available treatment options are far from optimal:
-
Open Surgery:
- Durable and life-long solution
- High-risk procedure
-
Endovascular Aneurysm Repair (EVAR):
- Lower immediate risks
- Shorter-term solution
- Requires continual monitoring and secondary interventions
Aortoseal Development
We have developed Aortoseal, a fixation and sealing implant for endovascular aneurysm repair that combines the best of both worlds:
- The stability of an open, sutured repair
- The safety and low-risk delivery of EVAR
Benefits of Aortoseal
Aortoseal will reduce:
- The need for open surgery
- The need for secondary procedures
- Time in the hospital
These improvements will lead to enhanced patient outcomes and projected healthcare savings over a 10-year period of approximately €9 billion across the EU.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 6.046.607 |
Tijdlijn
| Startdatum | 1-2-2023 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ENDORON MEDICAL LTD.penvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
World's first device-based treatment for small abdominal aortic aneurysms based on revolutionary new treatment paradigmThe Angiolutions device is a minimally-invasive implant that stabilizes small abdominal aortic aneurysms by increasing aortic stiffness, preventing life-threatening progression. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Revolutionary vascular repair patch to treat aortic dissectionsAortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Next-generation heart bypass grafts to naturally restore cardiovascular function.Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs. | EIC Accelerator | € 2.481.701 | 2022 | Details |
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry. | EIC Accelerator | € 2.497.469 | 2022 | Details |
World's first device-based treatment for small abdominal aortic aneurysms based on revolutionary new treatment paradigm
The Angiolutions device is a minimally-invasive implant that stabilizes small abdominal aortic aneurysms by increasing aortic stiffness, preventing life-threatening progression.
Revolutionary vascular repair patch to treat aortic dissections
Aortyx's biomimetic bioresorbable adhesive patch aims to treat aortic dissections via endovascular deployment, enhancing natural repair and reducing mortality compared to traditional stents.
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
Next-generation heart bypass grafts to naturally restore cardiovascular function.
Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs.
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)
AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Pushing Boundaries in Pre-clinical Aortopathy ResearchThis project aims to unravel mechanisms of syndromic thoracic aortic aneurysm and develop effective therapies using patient-derived aorta-on-a-chip models for pre-clinical research. | ERC Starting... | € 1.494.848 | 2024 | Details |
Redesigning aortic endograft: enabling in-situ personalized aneurysm healingEPEIUS aims to revolutionize aortic aneurysm treatment by developing a bioengineered, 3D-printed, drug-loaded endograft for early personalized healing through innovative in-vitro models. | ERC Consolid... | € 1.991.225 | 2024 | Details |
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profilesProtego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications. | ERC Starting... | € 1.498.295 | 2024 | Details |
OccluTex Coil HaalbaarheidsstudieHet project ontwikkelt een innovatieve embolisatiespoel met gecoate vezels om hersenaneurysma's effectief te vullen, kosten te verlagen en complicaties te verminderen. | Mkb-innovati... | € 20.000 | 2020 | Details |
LAPRIXA: the smallest organ blood pressure measurement device in the worldCorporis Medical ontwikkelt een innovatieve bloeddrukmeter om anastomotische lekkage bij slokdarm- en maagresecties te voorspellen. | Mkb-innovati... | € 20.000 | 2020 | Details |
Pushing Boundaries in Pre-clinical Aortopathy Research
This project aims to unravel mechanisms of syndromic thoracic aortic aneurysm and develop effective therapies using patient-derived aorta-on-a-chip models for pre-clinical research.
Redesigning aortic endograft: enabling in-situ personalized aneurysm healing
EPEIUS aims to revolutionize aortic aneurysm treatment by developing a bioengineered, 3D-printed, drug-loaded endograft for early personalized healing through innovative in-vitro models.
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profiles
Protego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications.
OccluTex Coil Haalbaarheidsstudie
Het project ontwikkelt een innovatieve embolisatiespoel met gecoate vezels om hersenaneurysma's effectief te vullen, kosten te verlagen en complicaties te verminderen.
LAPRIXA: the smallest organ blood pressure measurement device in the world
Corporis Medical ontwikkelt een innovatieve bloeddrukmeter om anastomotische lekkage bij slokdarm- en maagresecties te voorspellen.